Adjuvant Therapy Trends Post Resection in Pancreatic Cancer

Approximately 25.2% of pancreatic cancer patients who underwent upfront resection did not receive adjuvant therapy (AT), according to a prospective observational study. The main reasons for AT omission were postoperative complications, oncologist’s choice, baseline comorbidities, patient’s choice, and early recurrence. Older age, comorbidities, and postoperative complications were the main factors associated with AT omission. Additionally, older age, early-stage disease, and postoperative major complications were linked to not receiving a specific AT regimen called folfirinox. Patients experiencing postoperative complications also had a higher likelihood of delayed AT administration.